Research

UCLA Division of Rheumatology conducts cutting-edge biomedical and health-related research studies that include both interventional and observational studies. Our clinical studies are sponsored/funded by National Institute of Health (NIH), pharmaceutical companies, and/or non-profit medical institutions/organizations.

Treatment/Interventional studies are those in which the research subjects are assigned to a treatment or intervention and their outcomes are measured.

Observational studies are those in which individuals are observed and their outcomes are measured by the study investigators.

Return to Rheumatology Homepage

Current Clinical Studies

Rheumatoid Arthritis

Systemic Lupus Erythematosis

Scleroderma

Psoriatic Arthritis & Ankylosing Spondylitis

Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD)

If you would like to get more information on any studies please call us at (310) 825-0096 or email rheumresearch@mednet.ucla.edu.

If you are interested in finding out more information of a particular study, please contact the study personnel.

Study Type	Title of Study
RHEUMATOID ARTHRITIS
Treatment/Interventional	TARGET: To compare the effects on vascular inflammation of TNFi + MTX versus triple therapy in subjects with RA who are inadequate responders to MTX using FDG PET/CT as a tool for detecting vascular (arterial) inflammation.	Principal Investigators Christina Charles-Schoeman, MD, MS For more information contact Jeraldine 310-206-4007
Observational	Longitudinal Cardiovascular Risk Study of Patients with Rheumatoid Arthritis	Principal Investigators Christina Charles-Schoeman, MD, MS For more information contact Jeraldine 310-206-4007
Treatment	StopRA: Study to determine if hydroxychloroquine is safe and effective for the prevention of future onset of RA in people with elevated anti-CCP levels.	Principal Investigators Maureen McMahon, MD, MS For more information contact Julia 310-825-6461
Treatment	CANNABIS: Cannabis Anonymous Questionnaire in UCLA Rheumatology Patients.	Principal Investigators Veena K. Ranganath, MD, MS, RhMSUS
Treatment	ACTHAR: Use of ACTHAR in Rheumatoid Arthritis Related Flares.	Principal Investigators Veena K. Ranganath, MD, MS, RhMSUS
UPCOMING STUDIES
Treatment	CANNABIDIOL: Therapeutic Response of Cannabidiol in Rheumatoid Arthritis	Principal Investigators Veena K. Ranganath, MD, MS, RhMSUS
SYSTEMIC LUPUS ERYTHEMATOSIS
Observational	Precise: Looking for inpatient active lupus patients upon initial admission (prior to steroids) to follow longitudinally for disease activity.	Principal Investigators Jennifer King, MD, PhD For more information contact Samya 310-825-2548
Treatment	ALE09: Study to evaluate the efficacy, safety, and tolerability of lenabasum (synthetic cannabinoid) in decreasing pain associated with arthritis or tendonitis in lupus patients.	Principal Investigators Maureen McMahon, MD, MS For more information contact Julia 310-825-6461
Treatment	Eli Lilly JAHZ: Study to determine the effect of baricitinib and standard-of-care therapy on lupus disease activity.	Principal Investigators Jennifer Grossman, MD For more information contact Julia 310-825-6461
Observational	Pro-inflammatory HDL Cholesterol: Evaluating biomarkers of risk for atherosclerosis in lupus. Involves a one-time blood draw.	Principal Investigators Maureen McMahon, MD, MS For more information contact Lucas 310-825-2598
Treatment	IDEAL: Evaluating the value of educational information about the risks and benefits of lupus medications. Implementation of the DEcision-Aid for Lupus in practice settings for shared decision-making.	Principal Investigators Maureen McMahon, MD, MS For more information contact Julia 310-825-6461
Treatment	BMS PAISLEY: A study to evaluate the efficacy and safety of BMS-986165 in improving renal function in lupus nephritis patients who do not adequately respond to mycophenolate mofetil (MMF).	Principal Investigators Maureen McMahon, MD, MS For more information contact Julia 310-825-6461
UPCOMING STUDIES
Observational	GSK Belimumab in Early Lupus: A study to evaluate the effects of belimumab in patients recently diagnosed with lupus.	Principal Investigators Maureen McMahon, MD, MS For more information contact Julia 310-825-6461
Treatment	Amgen AMG570: A study evaluating the safety and efficacy AMG 570 in lupus patients.	Principal Investigators Maureen McMahon, MD, MS For more information contact Julia 310-825-6461
SCLERODERMA
Treatment	BRAVOS ITN075AI: Study of an Investigational Drug, Brentuximab Vedotin, for Diffuse Cutaneous Systemic Sclerosis	Principal Investigator Suzanne Kafaja, MD For more information, contact Isabel 310-825-9682
Treatment	Cumberland: A Study to Assess the Safety and Efficacy of Ifetroban in Patients with Diffuse Systemic Sclerosis or Systemic Sclerosis-Associated Pulmonary Arterial Hypertension	Principal Investigator Suzanne Kafaja, MD For more information, contact Isabel 310-825-9682
Treatment	CORBUS JBT101-SSc-002: A study to evaluate efficacy and safety of Lenabasum in diffuse cutaneous Systemic Sclerosis	Principal Investigator Suzanne Kafaja, MD For more information, contact Isabel 310-825-9682
Observational (Long-Term Follow-Up)	ASSET Long Term Follow-Up: A long term follow-up on ASSET: A study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis	Principal Investigator Suzanne Kafaja, MD For more information, contact Isabel 310-825-9682
Observational	GRASP: Genome Research in African American Scleroderma Patients (GRASP)	Principal Investigator Suzanne Kafaja, MD For more information, contact Isabel 310-825-9682
Observational	SPIN: The Scleroderma Patient-Centered Intervention Network (SPIN) cohort collecting data on a regular basis related to problems likely to be important for many people living with scleroderma	Principal Investigator Suzanne Kafaja, MD For more information, contact Isabel 310-825-9682
Observational	PI-Initiated: A study to define the differences in IMMUNE RESPONSES in skin from patients with an autoimmune or inflammatory condition	Principal Investigator Suzanne Kafaja, MD For more information, contact Isabel 310-825-9682
Treatment	SLS III: A combination study of pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma-related lung disease	Co-Principal Investigator Elizabeth Volkmann, MD, MS Co-Investigator Suzanne Kafaja, MD For more information, contact Isabel 310-825-9682
Treatment	SLS III: Mycophenolate vs. Mycophenolate + Pirfenidone for SSc-ILD	Co-Principal Investigator Elizabeth Volkmann, MD, MS For more information, contact Paul Lopez or Eileen Callahan 310-794-2466
Treatment	Forbius: A novel TGF-beta inhibitor for patients with diffuse cutaneous sclerosis	Principal Investigator Elizabeth Volkmann, MD, MS For more information, contact 310-990-3520
Treatment	CSL Behring: IVIG for patients with diffuse cutaneous sclerosis	Principal Investigator Elizabeth Volkmann, MD, MS For more information, contact 310-990-3520
Observational	SSc Microbiome study: Any patient with systemic sclerosis	Principal Investigator Elizabeth Volkmann, MD, MS For more information, contact 310-990-3520
Observational	The Gut Microbiome as a Screening Tool for ILD in SSc	Principal Investigator Elizabeth Volkmann, MD, MS For more information, contact 310-990-3520
Observational	Biomarkers to Predict Treatment Response in SSc-ILD	Principal Investigator Elizabeth Volkmann, MD, MS For more information, contact 310-990-3520
Observational	CURESSC - Consortium of Universities to REsearch Scleroderma in Southern California	Principal Investigator Elizabeth Volkmann, MD, MS For more information, contact 310-990-3520
Observational	Scleroderma Clinical Trial Consortium: The gastrointestinal Microbiome as a Marker of disease Activity in Systemic Sclerosis	Co-Principal Investigator Elizabeth Volkmann, MD, MS For more information, contact 310-990-3520
Treatment	Galapagos GLPG1690: A study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 (ATX inhibitor)	Principal Investigator Suzanne Kafaja, MD For more information, contact Isabel 310-825-9682
UPCOMING STUDIES
Treatment	Kadmon KD025-209: A study to evaluate the efficacy and safety of KD025 (ROCK2 inhibitor) in subjects with diffuse cutaneous Systemic Sclerosis	Principal Investigator Suzanne Kafaja, MD For more information, contact Isabel 310-825-9682
Treatment	Eicos ES-301: A study evaluating the safety and efficacy of IV Iloprost in subjects with systemic sclerosis experiencing symptomatic digital ischemic episodes	Principal Investigator Suzanne Kafaja, MD For more information, contact Isabel 310-825-9682
Treatment	IgPro10_2001: Study to evaluate the efficacy and safety of IgPro10 (intravenous immunoglobulin, Privigen®) for the treatment of adults with Systemic Sclerosis	Principal Investigator Suzanne Kafaja, MD For more information, contact Isabel 310-825-9682
PSORIATIC ARTHRITIS & ANKYLOSING SPONDYLITIS
Treatment	Novartis CAIN457F2354: A study to assess the time course of response to secukinumab on joint inflammation using Power Doppler ultrasonography in patients with active psoriatic arthritis	Principal Investigator Suzanne Kafaja, MD For more information, contact Isabel 310-825-9682
MYOSITIS
Observational	Longitudinal Cohort Study of Patients with Idiopathic Inflammatory Myopathies	Principal Investigators Christina Charles-Schoeman, MD, MS For more information contact Jeraldine 310-206-4007
Treatment	Corbus: Lenabasum for patients with active dermatomyositis	Principal Investigators Elizabeth Volkmann, MD, MS For more information contact Paul Lopez or Eileen Callahan 310-794-2466
UPCOMING STUDIES
Treatment/Interventional	CSL Behring: A study to evaluate the efficacy safety, and pharmacokinetics of IgPro20 (subcutaneous immunoglobulin, Hizentra®) in adults with dermatomyositis (DM)	Principal Investigators Christina Charles-Schoeman, MD, MS For more information contact Jeraldine 310-206-4007
SJOGREN'S SYNDROME
Observational	NGS Sjogren’s: Looking for primary Sjogren’s patients, both seropositive SSA+ or seronegative; especially with parotid swelling	Principal Investigator Jennifer King, MD For more information, contact Samya 310-825-2548
VASCULITIS
	No Studies at this time
GOUT
	No Studies at this time
UPCOMING STUDIES
	No Studies at this time
CONNECTIVE TISSUE DISEASE-INTERSTITIAL LUNG DISEASE (CTD-ILD)
Observational	CTD-ILD Registry: Any patient with a CTD-ILD	Principal Investigators Elizabeth Volkmann, MD, MS For more information contact Paul Lopez or Eileen Callahan 310-794-2466

UCLA Rheumatology

UCLA Rheumatology

Research

Research

Share this

Current Clinical Studies

Study Type

Title of Study